Next Article in Journal
Review on Compounds Isolated from Eriocaulaceae Family and Evaluation of Biological Activities by Machine Learning
Next Article in Special Issue
Amino-Acid-Conjugated Natural Compounds: Aims, Designs and Results
Previous Article in Journal
Microscopical Evaluation of the Effects of High-Pressure Processing on Milk Casein Micelles
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 27
Issue 21
10.3390/molecules27217187
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Sources, Transformations, Syntheses, and Bioactivities of Monoterpene Pyridine Alkaloids and Cyclopenta[c]pyridine Derivatives

by
Xuejian Zhang
1,2,
Feiyan Tao
1,2,3,*,
Tao Cui
1,
Cheng Luo
1,
Zhigang Zhou
1,
Yuchuan Huang
1,2,
Lanlan Tan
1,3,
Wei Peng
4 and
Chunjie Wu
4
1
Research and Development Centre, China Tobacco Sichuan Industrial Co., Ltd., Chengdu 610066, China
2
Sichuan Sanlian New Material Co., Ltd., Chengdu 610041, China
3
Harmful Components and Tar Reduction in Cigarette Sichuan Key Laboratory, Chengdu 610066, China
4
School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China
*
Author to whom correspondence should be addressed.
Molecules 2022, 27(21), 7187; https://doi.org/10.3390/molecules27217187
Submission received: 26 September 2022 / Revised: 14 October 2022 / Accepted: 20 October 2022 / Published: 24 October 2022
(This article belongs to the Special Issue Research Progress and Applications of Natural Products)
Browse Figures
Versions Notes

Abstract

:
Monoterpene pyridine alkaloids (MTPAs) are alkaloids derived from iridoid glycosides (IGs). The common molecular structure of MTPAs is the pyridine ring, while some of them have a cyclopenta[c]pyridine skeleton. Some compounds containing this structure are potentially bioactive medicinal agents. In this paper, seven drug candidates (A–G), ninety natural source products (1–90), thirty-seven synthesized compounds (91–127), as well as twenty-six key intermediates (S1–S26) were summarized. We categorized five types of MTPAs and one type of cyclopenta[c]pyridine alkaloids in all. Additionally, their possible genetic pathways were proposed. Then, the chemical transformation, biotransformation, chemical synthesis, as well as the bioactivity of MTPAs and cyclopenta[c]pyridine derivatives were analyzed and summarized. Cyclopenta[c]pyridine derivatives can be concisely and chirally synthesized, and they have shown potentials with antibacterial, insecticidal, antiviral, anti-inflammatory, and neuropharmacological activities.

1. Introduction

The nitrogen atom in pyridines, which are prized scaffolds in medicinal chemistry, is critical to the pharmacological profile of many medications that contain this heterocycle [1]. All monoterpene pyridine alkaloids (MTPAs) have a pyridine structure, most of which possessed a cyclopenta[c]pyridine molecular skeleton. Monoterpenes, mostly iridoid glycosides (IGs), are presumed to be biological or chemical synthetic precursors of MTPAs [2]. IGs are a class of substances with a structure resembling iridodial (Scheme 1 and Scheme 2), a chemical frequently used by plants as a defensive component.
Alkaloids are nitrogenous heterocyclic metabolites characterized by their structural diversity and bioactivity. Alkaloids are fundamental in organic chemistry and synthetic drug discovery. The pyridine structure in MTPAs is a functional molecular backbone widely found in natural products and bioactive molecules. The cyclopenta[c]pyridine or pyridine structure is a key fragment in a large proportion of bioactive compounds. Compounds containing cycloalkane pyridine have been used as intermediates in the synthesis of alkaloids or precursors of bioactive agents [3] (Figure 1). Compound A is a highly selective and potent aldosterone synthase inhibitor with an IC50 of 1 nM [4]. Ramelteon B’s 4-aza counterpart is a strong melatonin receptor agonist [5]. Additionally, the naturally occurring alkaloid sinensine C has shown cytoprotective action that may be helpful [5]. Compound D exhibited FXIIa inhibitory activity with an IC50 value in the range from 10 µM to 40 µM [6]. As a G-protein coupled receptor 40 (GPR40) agonist, compound E may be helpful in the treatment, suppression, and prevention of illnesses mediated by GPR40, including type 2 diabetes mellitus [7]. With IC50 values under 50 µM, compounds F and G are calcitonin gene-related peptide (CGRP) receptor antagonists that may be helpful in the treatment or prevention of CGRP-associated illnesses such as migraine or cluster headaches [8,9]. As a result, cyclopenta[c]pyridine-containing bioactive compounds are important research targets.
Due to the significance of the chemistry and bioactivity of MTPAs and cyclopenta[c]pyridine alkaloids, we focus on the structures of MTPAs and cyclopenta[c]pyridines, as well as their sources, chemical synthesis, and bioactivities in this review.

2. MTPAs and Their Activities

According to the different molecular skeletons and genetic pathways, we classified five types of transformation pathways from IGs to MTPAs. Five types were presented in Scheme 1: pyridine alkaloids derived from 4-demethyliridoids (Type I), pyridine alkaloids derived from iridoids (Type II), pyridine alkaloids derived from hemiacetal secoiridoids (Type III), pyridine alkaloids derived from secoiridoids (Type IV), and pyridines alkaloids derived from lactone secoiridoids (Type V). In addition, the phenyl-substituted cyclopenta[c]pyridine skeleton specifically existed in the genus Ganoderma (Type VI). In sum, Type I-V pyridine derivatives all originated from monoterpenoids. The Type I, II, and VI derivatives possessed the common cyclopenta[c]pyridine skeleton. Accordingly, this review has been organized in this manner. The category details in the following sections could help us obtain a clear picture of MTPAs and cyclopenta[c]pyridines, along with their origins, structures, sources, and bioactivities.
The ammonization and aromatization pathways from iridoids to pyridines were arranged and proposed (Scheme 2). Geraniol is an important precursor of MTPAs. Then, hydroxylation, oxidation and cyclization reactions on geraniol yield the intermediate iridoids [10]. Oxidation and hemiacetal formation lead to the production of the heterocyclic ring of iridoids [10]. Further ammonization and oxidation could provide the pyridine ring as follows (Scheme 2). At the beginning, secoiridoids are ammonified and dehydrated to afford enamines. Subsequently, nucleophilic addition/aromatization reactions of enamines could yield the pyridine ring.

2.1. Pyridine Alkaloids Derived from 4-Demethyliridoids (Figure 2, Table 1, Type I)

4-Demethypyridine alkaloids, processing the 8-methylcyclopenta[c]pyridine skeleton, are derived from iridoid through the oxidation of 4-methyl, decarboxylation of 4-carboxyl, ammonization, and aromatization (Scheme 1, Type I). In this section, nineteen 4-demethypyridine derivatives from plants are described, including three dimers (17–19).
Scrophularianine A (1), B (2), and C (3) were extracted and isolated from Scrophularia ningpoensis without using acids, bases, or nitrogen-containing salts [10]. In this case, these monoterpene alkaloids were thought to be natural MTPAs. MTPAs are mainly structurally related to iridoid compounds with the oxygen heterocycle being replaced by the pyridine ring.
Molecules 27 07187 g002 550
Figure 2. Structures of pyridine alkaloids derived from 4-demethyliridoids (Type I).
Figure 2. Structures of pyridine alkaloids derived from 4-demethyliridoids (Type I).
Molecules 27 07187 g002
Plumerianine (4) was isolated from Plumeria acutifolia (Apocynaceae), using aqueous ammonia for alkaloid extraction. The iridoid glycosides from P. acutifolia were unsaturated at C-6 and C-7, while plumerianine was saturated at C-6 and C-7. Therefore, the author believed that plumerianine (4) was not an artifact from iridoid glycosides, but rather a natural product [11].
The primary iridoids of Harpagophytum procumbens or Harpagophytum zeyheri, as well as harpagide, harpagoside, and 8-O-p-coumaroylharpagide were treated with NH3 and HCl to produce aucubinine B (5). A brown residue was produced by commercially available H. procumbens extract that had been first treated with ammonia and subsequently with hydrochloric acid. Aucubinine B (5), beatrine A (6), and beatrine B (7) were produced and separated from this residue [12]. Aucubinine B (5), coelobillardierine (8), and 7,8-dehydro-coelobillardierine (9) were obtained from ammonified extracts of Ceolospermun billardieri with NH4OH basification [13]. In a similar way, cantleyine I (11), 4-noractinidine (12), and pedicularine (13) were incompletely characterized from Castilleja miniate (Scrophulariaceae) and Penstemon whippleanus (Scrophulariaceae), both of which were the host plants for the plume moth Amblyptilia (Platyptifia) pica (Walsingham) [14]. In another case, Salviadiginine A (14) was isolated from the roots of Salvia digitaloids [15].
Table
Table 1. Pyridine alkaloids derived from 4-demethyliridoids (Type I).
Table 1. Pyridine alkaloids derived from 4-demethyliridoids (Type I).
Number Compound Name Source Reference
1 scrophularianine A Scrophularia ningpoensis [10]
2 scrophularianine B Scrophularia ningpoensis [10]
3 scrophularianine C Scrophularia ningpoensis [10]
4 plumerianine Plumeria acutifolia [11]
5 aucubinine B Harpagophytum procumbens, Ceolospermum billardieri, Caryopteris mongolica Bunge with basification of NH4OH [12,13]
6 beatrine A Harpagophytum procumbens[12]
7 beatrine B Harpagophytum procumbens [12]
8 coelobillardine Ceolospermum billardieri [13]
9 dehydro 7-8 coelobillardierine Ceolospermum billardieri [13]
10 (S)-7-Methylene-6,7-dihydro-5H-cyclopenta[c]pyridine-5-ol Caryopteris glutinosa with basification of NH4OH [16]
11 cantleyine I Castilleja miniata [14]
12 4-noractinidine Penstemon whippleanus [14]
13 pedicularine Penstemon whippleanus [14]
14 salviadiginine A Salvia digitaloids [15]
15 (5S*,7R*)-7-ethoxy-6,7-dihydro-7-methyl-5H-cyclopenta[c]pyridin-5-ol Caryopteris mongolica Bunge with basification of NH4OH [17]
16 caryopterisines F Caryopteris glutinosa with basification of NH4OH [16]
17 caryopterisines G Caryopteris glutinosa with basification of NH4OH [16]
18 caryopterisines H Caryopteris glutinosa with basification of NH4OH [16]
19 caryopterisines I Caryopteris glutinosa with basification of NH4OH [16]
20 Oxerine Caryopteris glutinosa with basification of NH4OH [16]
21 (5aR*,6S*,10S*,11R*,11aR*)-10,11a-dimethyl-6,7,9,10,11,11a-hexahydro-5H-6,11-epoxycyclopenta [6,7]azuleno[1,2-c]pyridin-5,8(5aH)-dione Caryopteris mongolica Bunge with basification of NH4OH [17]
22 (5aR*,6S*,7aR*,8S*,11aR*)-10-hydroxy-7a,11a-dimethyl-5a,6,7,7a,8,11a-hexahydro-5H-6,8-epoxycyclopenta[6,7]azuleno[1,2-c]pyridin-5-one Caryopteris mongolica Bunge with basification of NH4OH [17]
23 (6S*,6aR*,11R*,11aS*)-6a-hydroxy-11,11a-dimethyl-6,6a,11,11a-tetrahydro-5H-6,11-methanopyrido[3′,4′:4,5]cyclopenta[1,2-h]isoquinolin-5-one Caryopteris mongolica Bunge with basification of NH4OH [17]
24 caryopterisines C Caryopteris glutinosa with basification of NH4OH [16]
25 caryopterisines D Caryopteris glutinosa with basification of NH4OH [16]
26 caryopterisines E Caryopteris glutinosa with basification of NH4OH [16]
27 (5R*,5aR*,10bS*,11R*)-5-hydroxy-10b,11-dimethyl-5,5a,10b,11-tetrahydro-6H-5,11-methanopyrido[3′,4′:3,4]cyclopenta[1,2-g]isoquinolin-6-one
(±)-caryopterisines B 		Caryopteris mongolica Bunge with basification of NH4OH
Caryopteris glutinosa with basification of NH4OH 		[17,18]
28 (±)-caryopterisines A Caryopteris glutinosa with basification of NH4OH [18]
(5S*,7R*)-7-Ethoxy-6,7-dihydro-7-methyl-5H-cyclopenta[c]pyridin-5-ol (15), (5aR*,6S*,10S*,11R*,11aR*)-10,11a-dimethyl-6,7,9,10,11,11a-hexahydro-5H-6,11-epoxycyclopenta[6,7]azuleno[1,2-c]pyridin-5,8(5aH)-dione (21), (5aR*,6S*,7aR*,8S*,11aR*)-10-hydroxy-7a,11a-dimethyl-5a,6,7,7a,8,11a-hexahydro-5H-6,8-epoxycyclopenta[6,7]azuleno[1,2-c]pyridin-5-one (22), (6S*,6aR*,11R*,11aS*)-6a-hydroxy-11,11a-dimethyl-6,6a,11,11a-tetrahydro-5H-6,11-methanopyrido[3′,4′:4,5]cyclopenta[1,2-h]isoquinolin-5-one (23), and (5R*,5aR*,10bS*,11R*)-5-hydroxy-10b,11-dimethyl-5,5a,10b,11-tetrahydro-6H-5,11-methanopyrido[3′, 4′:3, 4]cyclopenta[1,2-g]isoquinolin-6-one (27) were isolated from the aerial parts of the Mongolian medicinal plant Caryopteris mongolica Bunge (Lamiaceae) with basification of NH4OH [17]. Compounds 15, 21–23, 27 were all reported with their relative configurations in this paper.
Subsequently, (±)-caryopterisines B (27) and A (28) with a 6/5/5/5/6 pentacyclic ring system were identified as racemates from Caryopteris glutinosa Rehder (Lamiaceae) [18]. Additionally, each of them underwent chiral HPLC examination, and computed ECD or X-ray diffraction analysis was used to determine their absolute configurations. In cell-based estrogen biosynthesis experiments, it was discovered that both 27 and 28 moderately reduced the manufacture of estrogen E2. Additionally, they moderately decreased kynurenine production by inhibiting indoleamine 2,3-dioxygenase [18]. It is possible for compound 28 to only slightly suppress interleukin-1β release [18].
(S)-7-Methylene-6,7-dihydro-5H-cyclopenta[c]pyridine-5-ol (10), caryopterisines F–I (16–19), oxerine (20), together with caryopterisines C–E (dimeric pyridine-containing alkaloids, 24–26) were characterized from C. glutinosa. The unprecedented dimers (24–26) may be biosynthetically or chemically transformed from a Diels–Alder reaction, a following aromatization rearrangement reaction, or a subsequent Baeyer–Villiger oxidation, and a set of following reactions. Inhibition activities of the nine alkaloids on collagen accumulation through a cell-based assay were carried out. Caryopterisines C (24) was indicated to be a potential lead compound with antifibrotic activities [16].

2.2. Pyridine Alkaloids Derived from Iridoids (Figure 3, Table 2, Type II)

4-Methylpyridine derivatives are directly ammoniated and aromatized from 4-methyliridoids. Eleven monomers (29–39) and two dimers (40–41) from plants were summarized in this class.
Molecules 27 07187 g003 550
Figure 3. Structures of pyridine alkaloids derived from iridoids (Type II).
Figure 3. Structures of pyridine alkaloids derived from iridoids (Type II).
Molecules 27 07187 g003
The volatile essential oil of Valeriana officinalis contains the chemicals actinidine (29) and valerianine (30), which are also present in a variety of iridoid-rich plants and insect species [19]. Similar to nepetalactone from catnip (Nepeta cataria), which is likewise a pheromone for insects and a defense component of rove beetles for several staphylinid species, the alkaloid (29), a product of two species of dolichoderine ants in the genus Conomyrma, attracts cats [19]. Actinidine (29), a psychotropic alkaloid that disrupts GABA-ergic metabolism and acts as an agonist on benzodiazepine receptors, causes an allosteric modification of the GABA-receptor proteins [19].
Previously, lysine and quinolinic acid were thought to be the biosynthesis precursors of actinidine [19]. Here, we believe that IGs are more likely to be the precursors of actinidine, which are similar to that of monoterpene indole alkaloids [20].
Additionally, two ant species, Tapinoma melanocephalum (Formicidae) and Iridomyrmex anceps Roger (Formicidae), as well as two plant species, Actinidia polygama Maxim (Actinidiaceae) and Nepeta cataria L. (Lamiaceae), all underwent heat induction to produce actinidine (29) [21].
Table
Table 2. Pyridine alkaloids derived from iridoids (Type II).
Table 2. Pyridine alkaloids derived from iridoids (Type II).
Number Compound Name Source Reference
29 actinidine Actinidia polygama; Valeriana officinalis[19,21]
30 valerianine Valeriana officinalis [19]
31 trans- p-coumaroyl -9-cantleyine Ceolospermum billardieri [13]
32 cis- p-coumaroyl -9-cantleyine Ceolospermum billardieri [13]
33 deoxyrhexifolin Castilleja rbexifolia; A purported hybrid of Castilleja rbexifolia and Castilleja miniata[22]
34 rhexifoline A purported hybrid of Castilleja rbexifolia and Castilleja miniate;
Transform of Penstemonoside 		[22,23]
35 cantleyine II Strychnos trinervis [24]
36 euphrosine Orthocarpus sp. [25]
37 10-acetoxy-actinidine Argylia radiata [26]
38 (+)-boscbniakine Penstemon whippleanus [14]
39 carbomethoxypedicularine Penstemon whippleanus [14]
40 a MTPA Dimer transformation from geniposide [27]
41 lindeniamine transformation from Lindenia austro-caledonica Brongn [28]
Extracts of Ceolospermun billardieri basified by NH4OH could afford not only compounds 5, 8 and 9, but also trans and cis p-coumaroyl -9-cantleyine (31 and 32) [13]. Similarly, rhexifoline (33) and deoxyrhexifoline (34) were two alkaloids isolated from the blossoms and seeds of Castilleja rhexifolia with basification of NH4OH [22]. Additionally, rhexifoline (33) was transformed from penstemonoside by means of treatment with NH3 [22,23]. Cantleyine II (35), a calcium channel inhibitor with properties akin to those of verapamil and nifedipine, was isolated from the root bark of Strychnos trinervis (a member of the family Loganiaceae). It was postulated that cantleyine II inhibits Ca2+ influx through voltage-gated Ca2+ channels, causing a reversible but nonselective spasmolytic activity on the vascular and visceral smooth muscles [24].
Euphrosine (36) was isolated from Ortbocarpus luteus. Compound 36 could be isolated with basification by NaOH/Na2CO3 (low yield: 0.003%) or aqueous NH3 (higher yield: 0.03%) [25]. Meanwhile, 10-Acetoxy-actinidine (37), whose structure was elucidated by Mass spectrometry and 1H NMR data, was isolated from the root of Argylia radiata (L.) D. Don [26]. Additionally, its structure was biogenetically related to iridoids present in this plant.
(+)-Boscbniakine (38) and carbomethoxypedicularine (39) were characterized from Castilleja miniate together with compounds 11, 12, and 13 by means of basification with NH4OH [14]. A MTPA dimer (40), a Diels–Alder adduct, was transformed from geniposide, which is an iridoid glycoside, reacting with β-glucosidase and aqueous NH4OAc [27]. Lindeniamine (41), another dimer, was isolated from Lindenia austro-caledonica Brongn (Rubiaceae), when ammonia was used in extraction [28].

2.3. Pyridine Alkaloids Derived from Hemiacetal Secoiridoids (Figure 4, Table 3, Type III)

In this section, five pyridine compounds 42–46 derived from the hemiacetal secoiridoid were described with the pyrano–pyridine ring. Compounds 42–44 and 46 were isolated from plants, while compound 45 was obtained through microbial transformation of an IG substrate.
Table
Table 3. Pyridine alkaloids derived from hemiacetal secoiridoids (Type III).
Table 3. Pyridine alkaloids derived from hemiacetal secoiridoids (Type III).
Number Compound Name Source Reference
42 (–)-vincapyridine A Vinca major [29]
43 (–)-vincapyridine B Vinca major [29]
44 (–)-vincapyridine C Vinca major [29]
45 gentianal transformation of gentiopicroside [30]
46 jasminin transformation of secoiridoid glucosides from Ligustrum vulgare L. [31]
Molecules 27 07187 g004 550
Figure 4. Pyridine alkaloids derived from hemiacetal secoiridoid (Type III).
Figure 4. Pyridine alkaloids derived from hemiacetal secoiridoid (Type III).
Molecules 27 07187 g004
(−)-Vinmajpyridines A–C (42–44) were isolated from the aerial parts of Vinca major (Apocynaceae) cultivated in Pakistan [29]. Gentianal (45) was yielded from the biotransformation of gentiopicroside by the asexual mycelia of Cordyceps sinensis [30]. However, jasminin (46) was isolated by treating secoiridoid glucosides from fruits of Ligustrum vulgare L. with H2SO4 and subsequently NH3.

2.4. Pyridine Alkaloids Derived from Secoiridoids (Figure 5, Table 4, Type IV)

In this class, pyridines were directly derived from secoiridoid through ammonization and aromatization as chemical transformations. There were five monomers and four dimers.
Methyl 5-ethylnicotinate (47), methyl 5-ethyl-4-methyl-nicotinate (48), p-hydroxy-β-phenethyI5-ethyl-3-methoxycarbonyl-4-pyridinylacetate (49), and 3,4-dihydroxy-β-phenylethyl-5-ethyl-3-methoxycarbonyl-4-pyridinylacetate (50) are pyridine alkaloids transformed from secoiridoid glucosides in Ligustrum vulgare L. [31,32,33], in the same way as 36. Meanwhile, p-hydroxy-β-phenetyl-PD-glucopyranoside 6-(5-ethyl-3-methoxycarbonyl)-4-pyridineacetate (51) [32], 4-methyl-5,5’-[(1-methyltrimethylen)di](methylnicotinate) (52), 4.4’-bis-methyl-5,5’-[(l-methyltrimethylen)di](methylnicotinate) (53), methyl 3,3′-bis-methoxycarbony1-5,5′-[(1-methyltrimethylene)di]-4,4′-bis-piridinylacetate (54), and methyl 5-[3-(3-methoxycarbonyI-5-pyridinyl)-l-methylpropyl]-3-methoxycarbonyl-4-pyridinylacetate (55) [33,34] were yielded in the same way.
Molecules 27 07187 g005 550
Figure 5. Structures of pyridine alkaloids derived from secoiridoids (Type IV).
Figure 5. Structures of pyridine alkaloids derived from secoiridoids (Type IV).
Molecules 27 07187 g005
Table
Table 4. Pyridine alkaloids derived from secoiridoids (Type IV).
Table 4. Pyridine alkaloids derived from secoiridoids (Type IV).
Number Compound Name Source Reference
47 methyl 5-ethylnicotinate transformation of secoiridoid glucosides from Ligustrum vulgare L. [31]
48 methyI5-ethyl-4-methyl-nicotinate transformation of secoiridoid glucosides from Ligustrum vulgare L. [31,32,33]
49 p-hydroxy-β-phenethyI5-ethyl-3-methoxycarbonyl-4-pyridinylacetate transformation of secoiridoid glucosides from Ligustrum vulgare L. [31,32,33]
50 3,4-dihydroxy-β-phenylethyl-5-ethyl-3-methoxycarbonyl-4-pyridinylacetate transformation of secoiridoid glucosides [33]
51 p-hydroxy-β-phenetyl-PD-glucopyranoside 6-(5-ethyl-3-methoxycarbonyl)-4-pyridineacetate transformation of secoiridoid glucosides from Ligustrum vulgare L. [32]
52 4-methyl-5,5′-[(1-methyltrimethylen)di](methylnicotinate) transformation of secoiridoid glucosides from Ligustrum vulgare L. [33,34]
53 4.4′-bis-methyl-5,5′-[(l-methyltrimethylen)di](methylnicotinate). transformation of secoiridoid glucosides from Ligustrum vulgare L. [33,34]
54 methyl 3,3′-bis-methoxycarbony1-5,5′-[(1-methyltrimethylene)di]-4,4′-bis-piridinylacetate transformation of secoiridoid glucosides [33]
55 methyl 5-[3-(3-methoxycarbonyI-5-pyridinyl)-l-methylpropyl]-3-methoxycarbonyl-4-pyridinylacetate transformation of secoiridoid glucosides [33]

2.5. Pyridines Alkaloids Derived from Lactone Secoiridoids (Figure 6, Table 5, Type V)

Here, three compounds are summarized. All of them possessed the pyridine fused δ-valerolactone skeleton and could be obtained from chemical transformation of IGs. Meanwhile, compound 57 could be yielded from biotransformation by fungi.
Gentianine (56) and (Z)-5-ethylidene-8-hydroxy-3,4,5,6,7,8-hexahydropyrano[3,4-c]pyridine-1-one (57) could be yielded in the same way as gentianal (45) [30,35]. Moreover, compound 57 could also be biotransformed from swertiamarin by Aspergillus niger [35]. Oliveramine (58) could be yielded in the same way as 52–55 [34]. Gentianine (56) was also isolated from Gentiana kirilowii, and many other Gentiana and Swertia species of the Gentianaceae family. Gentianine, which works as a CNS stimulant in low doses but transforms into a paralytic in greater levels, had its antipsychotic profile examined [36].
Molecules 27 07187 g006 550
Figure 6. Structures of pyridines alkaloids derived from lactone secoiridoids (Type V).
Figure 6. Structures of pyridines alkaloids derived from lactone secoiridoids (Type V).
Molecules 27 07187 g006
Table
Table 5. Pyridines alkaloids derived from lactone secoiridoids (Type V).
Table 5. Pyridines alkaloids derived from lactone secoiridoids (Type V).
Number Compound Name Source Reference
56 gentianine transformation of gentiopicroside [30]
57 (Z)-5-ethylidene-8-hydroxy-3,4,5,6,7,8-hexahydropyrano[3,4-c]pyridine-1-one biotransformation of gentiopicroside by asexual mycelia of Cordyceps sinensis; biotransformation of swertiamarin by Aspergillus niger[30,35]
58 oliveramine transformation from Gentiana olivieui[34]

2.6. Phenyl-Substituted Cyclopenta[c]pyridine Derivatives (Figure 7, Table 6, Type VI)

To date, twenty-six phenyl-substituted cyclopenta[c]pyridine compounds have been found exclusively in the genus Ganoderma. It was deduced that these uncommon alkaloids are probably biosynthesized via meroterpenoid and threonine [37]. In this case, there might be exclusive enzymes in this genus. Phenyl-substituted cyclopenta[c]pyridine may be an important chemtaxonomic characteristic to distinguish Ganoderma from other fungi.
Ganocochlearines A−I (69, 70, 59, 61–66), ganoapplanatumine B (60), sinensine E (67), and lucidimine C (68), most of which possessed a phenyl-substituted cyclopenta[c]pyridine skeleton, were obtained from the fruiting bodies of the fungus Ganoderma cochlear [37,38]. Among them, compounds 59–68 were all alkaloid enantiomers. Two alkaloid enantiomers [(±)-71 and (±)-67] were identified from Ganoderma luteomarginatum, a rare species in the genus Ganoderma, possessing the phenyl-substituted cyclopenta[c]pyridine skeleton [39]. To the best of our knowledge, only the genus Ganoderma has been associated with this type of skeleton in the natural world. Racemic cyclopenta[c]pyridines may indicate the presence of unique enzymes in Ganoderma.
Five alkaloids, sinensine A-E (72–76), were deduced from the fruiting bodies of Ganoderma sinense Zhao, Xu et Zhang, which is a traditional Chinese medicine [40,41]. With a protection rate of 70.90% and an EC50 value of 6.23 µmol/L, Sinensine A (72) exhibits activity in preventing the damage caused by hydrogen peroxide oxidation on human umbilical cord endothelial cells (HUVEC) [41].
The fruiting bodies of Ganoderma applanatum included the racemic ganoapplanatumines A (77), B (78) and epi-ganoapplanatumine B (79) [42].
The Ganoderma lucidum fruiting bodies contained the four polycylic alkaloids lucidimine A–D (80–83) [43]. Additionally, Ganoderma lucidum produced ganocochlearine A (69), which was separated and characterized. This compound demonstrated impressive neuroprotection with an EC50 value of 2.49 ± 0.12 μM and effective anti-inflammation with an IC50 value of 4.68 ± 0.09 μM [44]. Ganoderma australe’s fruiting bodies also yielded ganoochlearine A (69), which was able to considerably protect SH-SY5Y cells from glutamate-induced neural excitotoxicity at 10 μM and nearly reach its maximum efficacy at 20 μM [45].
The Ganoderma calidophilum fruiting body’s EtOAc extract was used to isolate compounds 84 (ganocalicine A) and 81 (lucidimine B/ganocalicine B). Compounds 81 and 84 strongly decreased the synthesis of IL-4 and LTB4 by RBL-2H3 cells in response to antigen stimulation and inhibited the activity of β-hexosaminidase (IC50 9.14 and 9.44 µM, respectively). This suggests that 81 and 84 have anti-allergic properties [46].
Table
Table 6. Phenyl-substituted Cyclopenta[c]pyridine Derivatives (Type VI).
Table 6. Phenyl-substituted Cyclopenta[c]pyridine Derivatives (Type VI).
NumberCompound NameSourceReference
59ganocochlearine CGanoderma cochlear[37,38]
60ganoapplanatumine BGanoderma cochlear[37,38]
61ganocochlearine DGanoderma cochlear[37,38]
62ganocochlearine EGanoderma cochlear[37,38]
63ganocochlearine FGanoderma cochlear[37,38]
64ganocochlearine GGanoderma cochlear[37,38]
65ganocochlearine HGanoderma cochlear[37,38]
66ganocochlearine IGanoderma cochlear[37,38]
67sinensine EGanoderma cochlear[37,38]
68lucidimine CGanoderma cochlear[37,38]
69ganocochlearine AGanoderma cochlear, Ganoderma lucidum, Ganoderma austral[37,38,44,45]
70ganocochlearine BGanoderma cochlear[37,38]
716-hydroxyganocochlearine AGanoderma luteomarginatum[39]
72sinensine AGanoderma sinense[40]
73sinensine BGanoderma sinense[40]
74sinensine CGanoderma sinense[40]
75sinensine DGanoderma sinense[40]
76sinensine EGanoderma sinense[40]
77ganoapplanatumine AGanoderma applanatum[42]
78ganoapplanatumine BGanoderma applanatum[42]
79epi-ganoapplanatumine BGanoderma applanatum[42]
80lucidimine AGanoderma lucidum[43]
81lucidimine B/ganocalicine BGanoderma lucidum, Ganoderma calidophilum[43,46]
82lucidimine CGanoderma lucidum[43]
83lucidimine DGanoderma lucidum[43]
84ganocalicine AGanoderma calidophilum[46]
Molecules 27 07187 g007 550
Figure 7. Structures of phenyl-substituted cyclopenta[c]pyridine derivatives (Type VI).
Figure 7. Structures of phenyl-substituted cyclopenta[c]pyridine derivatives (Type VI).
Molecules 27 07187 g007

3. Generation of MTPAs and Their Activities

Based on the available reports of MTPAs and cyclopenta[c]pyridines, these alkaloids have the five following origins: Firstly, these natural products are obtained without using nitrogen containing chemicals (concentrated ammonia, ammonium salts, etc.) in the extraction and separation process [10,19,26,29,32,34,39,47,48,49,50,51,52,53]; Secondly, some are products of the microbial biotransformation of iridoid glycosides [30,35,54,55,56,57]. Thirdly, these products may be artificial or natural, using nitrogen-containing chemicals in the extraction and separation process [11,12,13,14,22,28,58]. Fourthly, these products can be directly derived from the chemical transformation of iridoid glycosides with nitrogen-containing chemicals [23,25,27,31,33]. Fifthly, phenyl-substituted cyclopenta[c]pyridines only existed in the genus Ganoderma due to the special enzymes in these mushrooms [37,38,39,40,41,42,43,44,46].
In this paper, we summarized the chemical transformation, biotransformation, chemical synthesis, and bioactivities of the MTPAs and cyclopenta[c]pyridines. This could help us obtain a clear view of the chemistry and biology of MTPAs and cyclopenta[c]pyridines.

3.1. MTPAs Yielded by Chemical Transformation of IGs

Both (±)-27 and (±)-28 were supposed to be derived from 8-O-acetylharpagide, which is found in great quantities in the plant C. glutinosa. Naturally or in the presence of ammonia, 8-O-acetylharpagide may be converted to MTPAs (Scheme 3, intermediates: S1–S3, 9, and S4). The key step in their formation might be the Diels–Alder reaction of intermediates S3 and S4 to afford (±)-28 (exo type) and (±)-27 (endo type).
The selective amination of secoiridoid glycosides afforded monomeric pyridine alkaloids (48–50), dimeric pyridine alkaloids (52–55), and naphthyridine alkaloids (46), which was catalyzed by β-D-glucosidase. [33] (Scheme 4) The secoiridoid glucosides isolated from Ligustrum vulgare L. were subjected to 5 % H2SO4 and NH3 (gas) subsequently, affording compounds 46, 48, and 49 [31].
A series of iridoid glycosides treated by β-D-glucosidase and CH3COONH4 yielded MTPA monomers [8-epi-cantleyine 85 (Type II), corninine 86 (Type II), [7-(S)-acetoxy-5,6-(R, S)-dihydroxy-7(R)-methylcyclopenteno[c]pyridine 87 (Type I), racemigerine 88 (Type II)] and a dimer (40), accompanied by ammonium acetate or NH3 (g)/HCl (g) (Scheme 5A–E) [27]. The biogenic synthetic pathways of compound 40 are speculated upon in Scheme 6 [27], while the electron transfer of intermediate S10 is lightly revised, differing from the original article.
Penstemonoside was chemically converted to rhexifoline (34), which is shown in Scheme 5F. [23] At the same time, compound 34 was isolated from a hybrid species of Castilleja rbexifolia and Castilleja miniate by the same author, although aqueous ammonia was used in the extraction process [22].
It was found that pterocenoids A (Scheme 7, 89) and two other iridoid dimers from Pterocephalus hookeri exhibited moderate inhibitory activity in the NF-κB pathway. This was also consistent with the application of their botanical source, which is used to treat inflammatory disease in Tibetan herbal medicine. Therefore, it was supposed that such iridoid dimers were effective anti-inflammatory components [48].

3.2. MTPAs Generated from the Biotransformation of IGs

It has been reported that iridoid glycosides could be converted into MTPAs by fungi or human intestinal bacteria. Therefore, some researchers argued that the activities and potency of iridoid glycosides are attributed to their conversion to MPTAs [55].
As mentioned previously, Aspergillus niger could convert swertiamarin to naphthyridine (57, Scheme 8). In another case, the asexual mycelium of the fungus Cordyceps sinensis was able to convert gentiopicroside into compound 57 as well (Scheme 8) [19].
Harpagide, harpagoside, or 8-O-p-coumaroylharpagide could be transformed to aucubinine B (5) by human intestinal bacteria (Scheme 9A) [54]. It was reported that aucubin can be converted to aucubinines A (90, Type I) and B (5) by human intestinal bacteria [57], as shown in Scheme 9B.
In summary, both the chemical transformations and biotransformation of MTPAs form cyclopenta[c]pyridines molecular skeleton after amination of iridoids. Therefore, it is reasonable to speculate that MTPAs could be biosynthesized in a similar way by living organisms.

3.3. Chemical Synthesis of MPTAs/Cyclopenta[c]pyridines

In recent years, there have been many preeminent works on the total synthesis of MPTAs, and most of them employed one-step reaction to synthesize the target compounds. The early synthesis products were racemic, which was not reported in this paper. Additionally, all of the recent reports were chiral synthesis works, and are described in chronological order as follows.
In 2019, a straightforward tandem method for synthesizing pyridine derivatives in the absence of metals was described, and the chiral synthesis of (−)-actinidine (29) was finished in a single step (Scheme 10) [59].
An efficient and economical two-step synthesis of the cyclopenta[c]pyridines was reported, using an iridoid (genipin) as the substrate [2], as shown in Scheme 11. Additionally, the possible reaction mechanism was proposed, such as an aldol reaction. Compounds 91–112 were afforded in this way.
Li, L. et al. tested the anti-TMV activity of a series of synthesized cyclopenta[c]pyridine compounds (91–112, Scheme 11 and Figure 8). All the compounds were non-toxic against Nicotiana tabacum L. In subsequent anti-TMV activity tests, most of 91–112 showed good activities. Compound 109 [2-(4-methoxyphenyl)] had optimal anti-TMV activity with an inactivation effect of 40.2 ± 4.5%, a curative effect of 44.9 ± 4.0%, and a protection effect of 39.6 ± 2.3% at 500 μg/mL [2].
The insecticidal activities of the synthesized cyclopenta[c]pyridines 91–112 were also evaluated. Among those compounds, only compound 112 [2-(2-chloro-4-(trifluoromethoxy) phenyl)] exhibited activity against Plutella xylostella comparable to that of cerbinal, which was the natural precursor with an oxygen atom at the 2-position without modification. In view of this, the modification of the cyclopenta[c]pyridine skeleton at the 2-position significantly increased the anti-TMV activity but was not beneficial for insecticidal activity [2].
The molecular skeleton of cyclopenta[c]pyridines was constructed in a one-step reaction between 1,4-dibromo-1,3-butadienes and 2,5-disubstituted pyrroles, using one-carbon expansion of the pyrrole skeleton to pyridine (Scheme 12) [60]. Additionally, the reaction used Pd(OAc)2 (10%) and cyclopentadiene-phosphine (L1) as the catalysts. Cyclopenta[c]pyridine compounds 113–115 were afforded.
The Kondrat’eva reaction was used to prepare annulated pyridines directly in a flow device [4,5]. However, the reaction conditions of high temperature and pressure were needed, as depicted in Scheme 13. Cyclopenta[c]pyridine compounds 116–126 were yielded.
A divergent retrosynthetic analysis strategy (Scheme 14) was used to synthesize a series of iridoid derivatives, including actinidine (4) [61].
The total synthesis of (−)-plectrodorine (127) and (+)-oxerine (20) was completed in nine steps [62], using the oxazole–olefin Diels–Alder reaction (Scheme 15).
To sum up, the total synthesis of the molecular skeleton of MTPAs and cyclopenta[c]pyridines is becoming increasingly concise, efficient, economical, and green.

4. Conclusions

In total, we categorized six types of MTPAs and cyclopenta[c]pyridines by their origins and structures. MTPAs 1–58 and 75–90 originated from iridoids as natural, chemically transformed, enzyme catalyzed, or microbial transformed products. Phenyl-substituted cyclopenta[c]pyridine derivatives 59–84 were characteristic constituents in the genus Ganoderma and were proposed to be biosynthesized via meroterpenoid and threonine. To date, cyclopenta[c]pyridine compounds 4, 20, 29, and 91–127 have been concisely and chirally synthesized. The synthetic methods were concise, green, and productive. Additionally, MPTAs or cyclopenta[c]pyridines have shown potential with antibacterial, insecticidal, antiviral, and anti-inflammatory activities, as reported. It has been suggested that some of the iridoids were activated because of their transformations into MTPAs after ingestion. This was supported by the conversion of iridoids to MTPAs by intestinal microorganisms [55]. Meanwhile, iridoids are widely distributed and abundant in plants.
We believe that this paper will contribute to the further investigation of MTPAs and cyclopenta[c]pyridines regarding their origin, synthesis, and bioactivities. Therefore, further investigations of the chemistry and biology of MTPAs and cyclopenta[c]pyridines are expected.

Author Contributions

Conceptualization, F.T., C.W. and W.P.; investigation, X.Z., T.C. and L.T.; resources, Z.Z. and Y.H.; data curation, X.Z.; writing—original draft preparation, X.Z. and T.C.; writing—review and editing, X.Z. and T.C.; visualization, X.Z.; supervision, F.T. and C.L. All authors have read and agreed to the published version of the manuscript.

Funding

This research is supported by Sichuan Basic Research Program Foundation No. 2018JY0599.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

All data included in this review are available upon request by contact with the corresponding author.

Acknowledgments

The authors thank Lei Wu, Dandan Chang, Liutianyi Yang, Dikai Zhu, Yimin Wang and Yu Ding for studying the literatures and analyzing the data when preparing the manuscript.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Vitaku, E.; Smith, D.T.; Njardarson, J.T. Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among USA FDA approved pharmaceuticals. J. Med. Chem. 2014, 57, 10257–10274. [Google Scholar] [CrossRef]
  2. Li, L.; Zou, J.-Y.; You, S.; Deng, Z.; Liu, Y.; Wang, Q. Natural product cerbinal and its analogues cyclopenta [c] pyridines: Synthesis and discovery as novel pest control agents. J. Agric. Food Chem. 2019, 67, 10498–10504. [Google Scholar] [CrossRef] [PubMed]
  3. Dyachenko, I.V.; Dyachenko, V.D. Cycloalka [c] pyridine derivatives. Methods of synthesis and chemical properties. Russ. J. Org. Chem. 2017, 53, 1769–1787. [Google Scholar] [CrossRef]
  4. Martin, R.E.; Lehmann, J.; Alzieu, T.; Lenz, M.; Corrales, M.A.C.; Aebi, J.D.; Märki, H.P.; Kuhn, B.; Amrein, K.; Mayweg, A.V.; et al. Synthesis of annulated pyridines as inhibitors of aldosterone synthase (CYP11B2). Org. Biomol. Chem. 2016, 14, 5922–5927. [Google Scholar] [CrossRef] [PubMed]
  5. Lehmann, J.; Alzieu, T.; Martin, R.E.; Britton, R. The Kondrat’eva reaction in flow: Direct access to annulated pyridines. Org. Lett. 2013, 15, 3550–3553. [Google Scholar] [CrossRef] [PubMed]
  6. Childs, M.L.; Davie, R.L.; Edwards, H.J.; Evans, D.M.; Hodgson, S.T.; Mazzacani, A.; Clark, D.E.; Hinchliffe, P.S.; Baker, T.M.; Sambrook Smith, C.P.; et al. Carboxamides as Enzyme Inhibitors and Their Preparation. WO2021032938A1, 25 February 2021. [Google Scholar]
  7. Hagmann, W.K.; Nargund, R.P.; Blizzard, T.A.; Josien, H.; Biju, P.; Plummer, C.W.; Dang, Q.; Li, B.; Lin, L.S.; Cui, M.; et al. Preparation of Tricyclic Compounds as GPR40 Agonists for Use in Treating Diabetes and Associated Conditions. WO2014019186A1, 6 February 2014. [Google Scholar]
  8. Bell, I.; Selnick, H.; Zartman, C.B. 2’-Oxo-1’, 2’, 5, 7-Tetrahydrospiro [Cyclopenta [c] Pyridine-6,3’-Pyrrolo [2,3-b] Pyridine]-3-Carboxamide Derivatives as CGRP Receptor Antagonists and Their Preparation, Pharmaceutical Compositions and Use in the Treatment of Headaches. WO2008153849A1, 18 December 2008. [Google Scholar]
  9. Bell, I.M.; Selnick, H.G.; Stump, C.A. Preparation of Oxotetrahydrospiro[Cyclopentapyridinepyrrolo [2,3-b] Pyridinyl] Acetamides and Analogs Thereof as CGRP Receptor Antagonists. WO2008130512A1, 30 October 2008. [Google Scholar]
  10. Zhu, L.-J.; Hou, Y.-L.; Shen, X.-Y.; Pan, X.-D.; Zhang, X.; Yao, X.-S. Monoterpene pyridine alkaloids and phenolics from Scrophularia ningpoensis and their cardioprotective effect. Fitoterapia 2013, 88, 44–49. [Google Scholar] [CrossRef]
  11. Hassan, E.M.; Shahat, A.A.; Ibrahim, N.A.; Vlietinck, A.J.; Apers, S.; Pieters, L. A new monoterpene alkaloid and other constituents of Plumeria acutifolia. Planta Medica 2008, 74, 1749–1750. [Google Scholar] [CrossRef]
  12. Baghdikian, B.; Ollivier, E.; Faure, R.; Debrauwer, L.; Rathelot, P.; Balansard, G. Two new pyridine monoterpene alkaloids by chemical conversion of a commercial extract of Harpagophytum procumbens. J. Nat. Prod. 1998, 62, 211–213. [Google Scholar] [CrossRef]
  13. Lopez, J.L.; Pusset, J.; Feliciano, A.S. Plants of new-caledonia. 115. Monoterpene alkaloids from Coelospermum billardieri. J. Nat. Prod. 1988, 51, 829–835. [Google Scholar] [CrossRef]
  14. McCoy, J.W.; Stermitz, F.R. Chemistry of the scrophulariaceae. 2. Alkaloids from Castilleja miniata and Penstemon whippleanus, two host species for the plume moth, Amblyptilia (Platyptilia) pica. J. Nat. Prod. 1983, 46, 902–907. [Google Scholar] [CrossRef]
  15. Wu, S.-J.; Huang, C.-H.; Chan, Y.-Y.; Liao, Y.-R.; Hwang, T.-L.; Wu, T.-S. Two diterpenoids and a cyclopenta [c] pyridine derivative from roots of Salvia digitaloids. Int. J. Mol. Sci. 2014, 15, 11566–11577. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  16. Zhang, X.; Cao, Y.; Pan, D.; Yao, X.; Wang, F.; Zhang, G.; Luo, Y. Antifibrotic pyridine-containing monoterpene alkaloids from Caryopteris glutinosa. Phytochemistry 2022, 203, 113378. [Google Scholar] [CrossRef] [PubMed]
  17. Mishig, D.; Gruner, M.; Lübken, T.; Ganbaatar, C.; Regdel, D.; Knölker, H.-J. Isolation and structure elucidation of pyridine alkaloids from the aerial parts of the Mongolian medicinal plant Caryopteris mongolica Bunge. Sci. Rep. 2021, 11, 13740. [Google Scholar] [CrossRef] [PubMed]
  18. Zhang, X.; Luo, G.; Cao, Y.; Mishig, D.; Lodonjav, M.; Pan, D.; Yao, X.; Wang, F.; Zhang, G.; Luo, Y. (±)-Caryopterisines A and B, dimeric monoterpene alkaloids with unprecedented 6/5/5/5/6 pentacyclic rings scaffold from Caryopteris glutinosa. Bioorg. Chem. 2021, 116, 105364. [Google Scholar] [CrossRef] [PubMed]
  19. Patocka, J.; Jaki, J. Biomedically relevant chemical constituents of Valeriana officinalis. J. Appl. Biomed. 2010, 8, 11–18. [Google Scholar] [CrossRef] [Green Version]
  20. O’Connor, S.E.; Maresh, J.J. Chemistry and biology of monoterpene indole alkaloid biosynthesis. Nat. Prod. Rep. 2006, 23, 532–547. [Google Scholar] [CrossRef]
  21. Shi, Q.; He, Y.; Chen, J.; Lu, L. Thermally induced actinidine production in biological samples. J. Agric. Food Chem. 2020, 68, 12252–12258. [Google Scholar] [CrossRef]
  22. Roby, M.R.; Stermitz, F.R. Pyrrolizidine and pyridine monoterpene alkaloids from 2 castilleja plant hosts of the plume moth, Platyptilia pica. J. Nat. Prod. 1984, 47, 846–853. [Google Scholar] [CrossRef]
  23. Roby, M.R.; Stermitz, F.R. Chemistry of the scrophulariaceae. 4. Penstemonoside and other iridoids from Castilleja rhexifolia. Conversion of penstemonoside to the pyridine monoterpene alkaloid rhexifoline. J. Nat. Prod. 1984, 47, 854–857. [Google Scholar] [CrossRef]
  24. Da Silva, T.; Da Silva, B.; Mukherjee, R. The monoterpene alkaloid cantleyine from Strychnos trinervis root and its spasmolytic properties. Phytomedicine 1999, 6, 169–176. [Google Scholar] [CrossRef]
  25. Boros, C.A.; Stermitz, F.R.; Harris, G.H. Iridoid glycosides and a pyridine monoterpene alkaloid from Orthocarpus. New artifactual iridoid dienals. J. Nat. Prod. 1990, 53, 72–80. [Google Scholar] [CrossRef]
  26. Bianco, A.; Bonadies, F.; Cianciolo, V.; Melchioni, C.; Ramunno, A.; Dezzi, S.; Nicoletti, M.; Serafini, M.; Ballero, M. Monoterpene alkaloids from Argylia radiata. Nat. Prod. Lett. 2002, 16, 77–80. [Google Scholar] [CrossRef] [PubMed]
  27. Frederiksen, S.M.; Stermitz, F.R. Pyridine monoterpene alkaloid formation from iridoid glycosides. A novel pmta dimer from geniposide. J. Nat. Prod. 1996, 59, 41–46. [Google Scholar] [CrossRef] [PubMed]
  28. Saad, H.; Anton, R.; Quirion, J.; Chauvière, G.; Pusset, J. New-caledonian plants.116.(1) Lindenialine and lindeniamine, two new iridoids from Lindenia austro-caledonica brongn. Tetrahedron Lett. 1988, 29, 615–618. [Google Scholar] [CrossRef]
  29. Wei, X.; Khan, A.; Song, D.; Dai, Z.; Liu, Y.-P.; Yu, H.-F.; Wang, B.; Zhu, P.-F.; Ding, C.-F.; Zhao, X.-D.; et al. Three new pyridine alkaloids from Vinca major cultivated in Pakistan. Nat. Prod. Bioprospect. 2017, 7, 323–327. [Google Scholar] [CrossRef] [Green Version]
  30. Wang, D.; Xu, M.; Zhu, H.-T.; Chen, K.-K.; Zhang, Y.-J.; Yang, C.-R. Biotransformation of gentiopicroside by asexual mycelia of Cordyceps sinensis. Bioorganic Med. Chem. Lett. 2007, 17, 3195–3197. [Google Scholar] [CrossRef]
  31. Willems, M. Transformation of Secoiridoid Glucosides to Pyridine Alkaloids. Arch. der Pharm. 1987, 320, 1245–1248. [Google Scholar] [CrossRef]
  32. Willems, M. A Glucosidic alkaloid artifact, originated from secoiridoid glucosides from fruits of Ligustrum vulgare L. Arch. der Pharm. 1988, 321, 357–358. [Google Scholar] [CrossRef]
  33. Ranarivelo, Y.; Magiatis, P.; Skaltsounis, A.-L.; Tillequin, F. Selective amination of secoiridoid glycosides to give monomeric pyridine, dimeric pyridine, and naphthyridine alkaloids. Nat. Prod. Lett. 2001, 15, 131–137. [Google Scholar] [CrossRef]
  34. Willems, M. Dimeric pyridine alkaloids. Artifacts, originating from secoiridoid glucosides from Ligustrum vulgare L. Arch. Pharm. 1988, 321, 229–330. [Google Scholar] [CrossRef]
  35. Chang, J.; Zhou, B. Biotransformation of swertiamarin by Aspergillus niger. Pak. J. Pharm. Sci. 2015, 28, 1933–1937. [Google Scholar]
  36. Bhattacharya, S.K.; Ghosal, S.; Chaudhuri, R.K.; Singh, A.K.; Sharma, P.V. Letter: Chemical constituents of gentianaceae. XI. Antipsychotic activity of gentianine. J. Pharm. Sci. 1974, 63, 1341–1342. [Google Scholar] [CrossRef] [PubMed]
  37. Wang, X.-L.; Dou, M.; Luo, Q.; Cheng, L.-Z.; Yan, Y.-M.; Li, R.-T.; Cheng, Y.-X. Racemic alkaloids from the fungus Ganoderma cochlear. Fitoterapia 2017, 116, 93–98. [Google Scholar] [CrossRef] [PubMed]
  38. Tian, L.; Wang, X.L.; Wang, Y.Z.; Cheng, Y.X. Two new alkaloids from Ganoderma cochlear. Nat. Prod. Res. Dev. 2015, 27, 1325–1328. [Google Scholar]
  39. Li, X.-C.; Liu, F.; Su, H.-G.; Guo, L.; Zhou, Q.-M.; Huang, Y.-J.; Peng, C.; Xiong, L. Two pairs of alkaloid enantiomers from Ganoderma luteomarginatum. Biochem. Syst. Ecol. 2019, 86, 103930. [Google Scholar] [CrossRef]
  40. Liu, J.-Q.; Wang, C.-F.; Peng, X.-R.; Qiu, M.-H. New alkaloids from the fruiting bodies of Ganoderma sinense. Nat. Prod. Bioprospect. 2011, 1, 93–96. [Google Scholar] [CrossRef] [Green Version]
  41. Liu, C.; Zhao, F.; Chen, R. A novel alkaloid from the fruiting bodies of Ganoderma sinense Zhao, Xu et Zhang. Chin. Chem. Lett. 2010, 21, 197–199. [Google Scholar] [CrossRef]
  42. Luo, Q.; Yang, X.-H.; Yang, Z.-L.; Tu, Z.-C.; Cheng, Y.-X. Miscellaneous meroterpenoids from Ganoderma applanatum. Tetrahedron 2016, 72, 4564–4574. [Google Scholar] [CrossRef]
  43. Zhao, Z.Z.; Chen, H.P.; Feng, T.; Li, Z.H.; Dong, Z.J.; Liu, J.K. Lucidimine A-D, four new alkaloids from the fruiting bodies of Ganoderma lucidum. J. Asian Nat. Prod. Res. 2015, 17, 1160–1165. [Google Scholar] [CrossRef]
  44. Lu, S.-Y.; Peng, X.-R.; Dong, J.-R.; Yan, H.; Kong, Q.-H.; Shi, Q.-Q.; Li, D.-S.; Zhou, L.; Li, Z.-R.; Qiu, M.-H. Aromatic constituents from Ganoderma lucidum and their neuroprotective and anti-inflammatory activities. Fitoterapia 2019, 134, 58–64. [Google Scholar] [CrossRef]
  45. Zhang, J.-J.; Dong, Y.; Qin, F.-Y.; Yan, Y.-M.; Cheng, Y.-X. Meroterpenoids and alkaloids from Ganoderma australe. Nat. Prod. Res. 2019, 35, 3226–3232. [Google Scholar] [CrossRef] [PubMed]
  46. Huang, S.Z.; Cheng, B.H.; Ma, Q.Y.; Wang, Q.; Kong, F.D.; Dai, H.F.; Qiu, S.Q.; Zheng, P.Y.; Liu, Z.Q.; Zhao, Y.X. Anti-allergic Prenylated Hydroquinones and Alkaloids from the fruiting body of Ganoderma calidophilum. RSC Adv. 2016, 6, 21139–21147. [Google Scholar] [CrossRef]
  47. Zhang, J.F.; Huang, S.; Shan, L.H.; Chen, L.; Zhang, Y.; Zhou, X.L. New iridoid glucoside from Pterocephalus hookeri. Chin. J. Org. Chem. 2015, 35, 2441–2444. [Google Scholar] [CrossRef] [Green Version]
  48. Wu, Y.-C.; Guo, C.-X.; Zhu, Y.-Z.; Li, Y.-M.; Guo, F.-J.; Zhu, G.-F. Four new bis-iridoids isolated from the traditional Tibetan herb Pterocephalus hookeri. Fitoterapia 2014, 98, 104–109. [Google Scholar] [CrossRef] [PubMed]
  49. Li, F.; Tanaka, K.; Watanabe, S.; Tezuka, Y.; Saiki, I. Dipasperoside A, a novel pyridine alkaloid-coupled iridoid glucoside from the roots of Dipsacus asper. Chem. Pharm. Bull. 2013, 61, 1318–1322. [Google Scholar] [CrossRef] [Green Version]
  50. Huang, J.-G.; Zhou, L.-J.; Xu, H.-H. Two new constituents from Torricellia tiliifolia stem barks. Helv. Chim. Acta 2011, 94, 327–330. [Google Scholar] [CrossRef]
  51. Dembitsky, V.M. Astonishing diversity of natural surfactants: 6. Biologically active marine and terrestrial alkaloid glycosides. Lipids 2005, 40, 1081–1105. [Google Scholar] [CrossRef]
  52. Saxena, J.; Mathela, C.S. Antifungal activity of new compounds from Nepeta leucoyhylla and Nepeta clarkei. Appl. Environ. Microbiol. 1996, 62, 702–704. [Google Scholar] [CrossRef] [Green Version]
  53. Takahashi, A.; Ikeda, D.; Nakamura, H.; Naganawa, H.; Kurasawa, S.; Okami, Y.; Takeuchi, T.; Iitaka, Y. Altemicidin, a new acaricidal and antitumor substance. II. Structure determination. J. Antibiot. 1989, 42, 1562–1566. [Google Scholar] [CrossRef]
  54. Baghdikian, B.; Guiraud-Dauriac, H.; Ollivier, E.; N’Guyen, A.; Dumenil, G.; Balansard, G. Formation of nitrogen-containing metabolites from the main iridoids of Harpagophytum procumbens and H. zeyheri by human intestinal bacteria. Planta Med. 1999, 65, 164–166. [Google Scholar] [CrossRef]
  55. Ghisalberti, E. Biological and pharmacological activity of naturally occurring iridoids and secoiridoids. Phytomedicine 1998, 5, 147–163. [Google Scholar] [CrossRef]
  56. Kawata, Y.; Hattori, M.; Akao, T.; Kobashi, K.; Namba, T. Formation of nitrogen-containing metabolites from geniposide and gardenoside by human intestinal bacteria. Planta Med. 1991, 57, 536–542. [Google Scholar] [CrossRef] [PubMed]
  57. Hattori, M.; Kawata, Y.; Inoue, K.; Shu, Y.; Che, Q.; Namba, T.; Kobashi, K. Transformation of aucubin to new pyridine monoterpene alkaloids, aucubinines A and B, by human intestinal bacteria. Phytother. Res. 1990, 4, 66–70. [Google Scholar] [CrossRef]
  58. Cheng, G.G.; Li, D.; Hou, B.; Li, X.N.; Liu, L.; Chen, Y.Y.; Lunga, P.K.; Khan, A.; Liu, Y.P.; Zuo, Z.L.; et al. Melokhanines A-J, bioactive monoterpenoid indole alkaloids with diverse skeletons from Melodinus khasianus. J. Nat. Prod. 2016, 79, 2158–2166. [Google Scholar] [CrossRef] [PubMed]
  59. Uredi, D.; Motati, D.R.; Watkins, E.B. A simple, tandem approach to the construction of pyridine derivatives under metal-free conditions: A one-step synthesis of the monoterpene natural product, (−)-actinidine. Chem. Commun. 2019, 55, 3270–3273. [Google Scholar] [CrossRef]
  60. Yin, J.; Ye, Q.; Hao, W.; Du, S.; Gu, Y.; Zhang, W.X.; Xi, Z. Formation of cyclopenta [c] pyridine derivatives from 2,5-Disubstituted pyrroles and 1,4-Dibromo-1,3-butadienes via Pyrrole-Ring One-Carbon expansion. Org. Lett. 2017, 19, 138–141. [Google Scholar] [CrossRef]
  61. Beckett, J.S.; Beckett, J.D.; Hofferberth, J.E. A divergent approach to the diastereoselective synthesis of several ant-associated iridoids. Org. Lett. 2010, 12, 1408–1411. [Google Scholar] [CrossRef]
  62. Ohba, M.; Izuta, R.; Shimizu, E. Use of the oxazole-olefin diels-alder reaction in the total synthesis of the monoterpene alkaloids (-)-plectrodorine and (+)-oxerine. Chem. Pharm. Bull. 2006, 54, 63–67. [Google Scholar] [CrossRef]
Molecules 27 07187 g001 550
Figure 1. Examples of bioactive cyclopenta[c]pyridine derivatives.
Figure 1. Examples of bioactive cyclopenta[c]pyridine derivatives.
Molecules 27 07187 g001
Molecules 27 07187 sch001 550
Scheme 1. Possible genetic pathways from iridoids to MTPAs.
Scheme 1. Possible genetic pathways from iridoids to MTPAs.
Molecules 27 07187 sch001
Molecules 27 07187 sch002 550
Scheme 2. Possible ammonization and aromatization pathway from iridoids to MTPAs.
Scheme 2. Possible ammonization and aromatization pathway from iridoids to MTPAs.
Molecules 27 07187 sch002
Molecules 27 07187 sch003 550
Scheme 3. Proposed genetic pathway for (±)-27 and (±)-28.
Scheme 3. Proposed genetic pathway for (±)-27 and (±)-28.
Molecules 27 07187 sch003
Molecules 27 07187 sch004 550
Scheme 4. Amination of secoiridoid glycosides ((A), oleuropein and ligstroside as substrates; (B), methyloleoside as substrates) to give monomeric pyridine, dimeric pyridine, and naphthyridine alkaloids.
Scheme 4. Amination of secoiridoid glycosides ((A), oleuropein and ligstroside as substrates; (B), methyloleoside as substrates) to give monomeric pyridine, dimeric pyridine, and naphthyridine alkaloids.
Molecules 27 07187 sch004
Molecules 27 07187 sch005 550
Scheme 5. MTPAs produced from IGs.
Scheme 5. MTPAs produced from IGs.
Molecules 27 07187 sch005
Molecules 27 07187 sch006 550
Scheme 6. Possible transformation mode to afford a monomeric MTPA (88) and the dimeric MTPA (40).
Scheme 6. Possible transformation mode to afford a monomeric MTPA (88) and the dimeric MTPA (40).
Molecules 27 07187 sch006
Molecules 27 07187 sch007 550
Scheme 7. Possible biosynthetic route of compound 89.
Scheme 7. Possible biosynthetic route of compound 89.
Molecules 27 07187 sch007
Molecules 27 07187 sch008 550
Scheme 8. Compound 57 yielded from Aspergillus niger (A) or Cordyceps sinensis (B) by means of biotransformation.
Scheme 8. Compound 57 yielded from Aspergillus niger (A) or Cordyceps sinensis (B) by means of biotransformation.
Molecules 27 07187 sch008
Molecules 27 07187 sch009 550
Scheme 9. Conversion of three harpagide congeners to aucubinine B (5) by β-glucosidase in the presence of NH4OAc or by human intestinal flora (A); possible metabolic processes of aucubin by human intestinal bacteria (B).
Scheme 9. Conversion of three harpagide congeners to aucubinine B (5) by β-glucosidase in the presence of NH4OAc or by human intestinal flora (A); possible metabolic processes of aucubin by human intestinal bacteria (B).
Molecules 27 07187 sch009
Molecules 27 07187 sch010 550
Scheme 10. One-step synthesis of the monoterpene natural product, (−)-actinidine (29).
Scheme 10. One-step synthesis of the monoterpene natural product, (−)-actinidine (29).
Molecules 27 07187 sch010
Molecules 27 07187 g008 550
Figure 8. Cyclopenta[c]pyridine products (91–112) obtained from a concise biomimic access.
Figure 8. Cyclopenta[c]pyridine products (91–112) obtained from a concise biomimic access.
Molecules 27 07187 g008
Molecules 27 07187 sch011 550
Scheme 11. (A), Synthesis of cyclopenta[c]pyridine from genipin; (B), possible reaction mechanism.
Scheme 11. (A), Synthesis of cyclopenta[c]pyridine from genipin; (B), possible reaction mechanism.
Molecules 27 07187 sch011
Molecules 27 07187 sch012 550
Scheme 12. Reactions afforded cyclopenta[c]pyridine derivatives.
Scheme 12. Reactions afforded cyclopenta[c]pyridine derivatives.
Molecules 27 07187 sch012
Molecules 27 07187 sch013 550
Scheme 13. The Kondrat’eva Reaction in Flow: synthesis of annulated pyridines.
Scheme 13. The Kondrat’eva Reaction in Flow: synthesis of annulated pyridines.
Molecules 27 07187 sch013
Molecules 27 07187 sch014 550
Scheme 14. Diastereoselective synthesis of actinidine (4).
Scheme 14. Diastereoselective synthesis of actinidine (4).
Molecules 27 07187 sch014
Molecules 27 07187 sch015 550
Scheme 15. Total synthesis of the monoterpene alkaloids (−)-plectrodorine (127) and (+)-oxerine (20).
Scheme 15. Total synthesis of the monoterpene alkaloids (−)-plectrodorine (127) and (+)-oxerine (20).
Molecules 27 07187 sch015
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Zhang, X.; Tao, F.; Cui, T.; Luo, C.; Zhou, Z.; Huang, Y.; Tan, L.; Peng, W.; Wu, C. Sources, Transformations, Syntheses, and Bioactivities of Monoterpene Pyridine Alkaloids and Cyclopenta[c]pyridine Derivatives. Molecules 2022, 27, 7187. https://doi.org/10.3390/molecules27217187

AMA Style

Zhang X, Tao F, Cui T, Luo C, Zhou Z, Huang Y, Tan L, Peng W, Wu C. Sources, Transformations, Syntheses, and Bioactivities of Monoterpene Pyridine Alkaloids and Cyclopenta[c]pyridine Derivatives. Molecules. 2022; 27(21):7187. https://doi.org/10.3390/molecules27217187

Chicago/Turabian Style

Zhang, Xuejian, Feiyan Tao, Tao Cui, Cheng Luo, Zhigang Zhou, Yuchuan Huang, Lanlan Tan, Wei Peng, and Chunjie Wu. 2022. "Sources, Transformations, Syntheses, and Bioactivities of Monoterpene Pyridine Alkaloids and Cyclopenta[c]pyridine Derivatives" Molecules 27, no. 21: 7187. https://doi.org/10.3390/molecules27217187

APA Style

Zhang, X., Tao, F., Cui, T., Luo, C., Zhou, Z., Huang, Y., Tan, L., Peng, W., & Wu, C. (2022). Sources, Transformations, Syntheses, and Bioactivities of Monoterpene Pyridine Alkaloids and Cyclopenta[c]pyridine Derivatives. Molecules, 27(21), 7187. https://doi.org/10.3390/molecules27217187

Article Metrics

Back to TopTop